Evommune, Inc.(EVMN)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,859 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in EVMN
Events flagged as statistical outliers against EVMN's own multi-year baseline — not fixed dollar thresholds.
- Insider cluster2026-07-08
2 insiders bought $146,260 of EVMN in 30 days — 3.9σ above this company's 2-year norm
View source filing →
EVMN Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Evommune, Inc. (EVMN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores EVMN at 14.9/100 on a 32-signal composite quality model, placing it at rank #2,859 of 2,961 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue scale (2.1) and free cash flow (2.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 5.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Evommune, Inc. reports net income of $-32.2M, free cash flow of $-20.5M. Top institutional holders of EVMN by reported 13-F value include EQT Fund Management S.a r.l., RA CAPITAL MANAGEMENT, L.P., PRICE T ROWE ASSOCIATES, based on the most recent SEC filings. EVMN trades on the NYSE exchange and files with the SEC under CIK 2044725. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EVMN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Evommune, Inc. directly from SEC EDGAR. Evommune, Inc.'s 13F Pro composite quality score has ranged between 14 and 27 since 2026, currently 14.9 — a stable long-term trajectory across 19 quarterly and live scoring snapshots.
Revenue
Q2 2026
$0.00
Net Income
Q2 2026
$-32.2M
Free Cash Flow
Q2 2026
$-20.5M
ROIC
Q2 2026
-50.3%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+85.7% YoYNet Income
-3.1% YoYOperating Income
-15.8% YoYEPS (Diluted)
+75.2% YoYTotal Assets
+195.8% YoYOp. Cash Flow
-31.4% YoYFree Cash Flow
-31.6% YoY| Metric | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | $13.0M +85.7% | $7.0M | — |
| Net Income | $-68.9M -3.1% | $-66.8M | — |
| Operating Income | $-81.1M -15.8% | $-70.0M | — |
| EPS (Diluted) | $-11.22 +75.2% | $-45.29 | — |
| Total Assets | $224.9M +195.8% | $76.1M | — |
| Operating Cash Flow | $-76.4M -31.4% | $-58.2M | — |
| Free Cash Flow | $-76.7M -31.6% | $-58.3M | — |
Get alerted when EVMN's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Evommune, Inc. including:
Top Institutional Holders of EVMN
EQT Fund Management S.a r.l.
$70.3M5,288,313 shRA CAPITAL MANAGEMENT, L.P.
$46.4M3,494,638 shPRICE T ROWE ASSOCIATES INC /MD/
$25.8M1,940,939 shPivotal bioVenture Partners Investment Advisor LLC
$25.6M1,926,943 shJPMORGAN CHASE & CO
$23.4M1,553,132 shRTW INVESTMENTS, LP
$20.0M1,502,235 shNan Fung Group Holdings Ltd
$19.2M1,441,032 shPoint72 Asset Management, L.P.
$19.1M1,435,049 shAndera Partners
$18.5M1,391,990 shEVENTIDE ASSET MANAGEMENT, LLC
$16.1M1,209,129 sh
| Fund | Value | Shares |
|---|---|---|
| EQT Fund Management S.a r.l. | $70.3M | 5,288,313 |
| RA CAPITAL MANAGEMENT, L.P. | $46.4M | 3,494,638 |
| PRICE T ROWE ASSOCIATES INC /MD/ | $25.8M | 1,940,939 |
| Pivotal bioVenture Partners Investment Advisor LLC | $25.6M | 1,926,943 |
| JPMORGAN CHASE & CO | $23.4M | 1,553,132 |
| RTW INVESTMENTS, LP | $20.0M | 1,502,235 |
| Nan Fung Group Holdings Ltd | $19.2M | 1,441,032 |
| Point72 Asset Management, L.P. | $19.1M | 1,435,049 |
| Andera Partners | $18.5M | 1,391,990 |
| EVENTIDE ASSET MANAGEMENT, LLC | $16.1M | 1,209,129 |
Companies Similar to EVMN
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Zenas BioPharma, Inc.
BioAge Labs, Inc.
Wave Life Sciences, Inc.
Avalo Therapeutics, Inc.
Prelude Therapeutics Inc
Xencor Inc
Taysha Gene Therapies, Inc.
IDEAYA Biosciences, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put EVMN on your watchlist
Track score changes the day Evommune, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is EVMN a good stock to buy?
13F Pro's AI-powered analysis of Evommune, Inc. (EVMN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for EVMN are available on the EVMN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. EVMN is classified as a small company.
Which hedge funds own EVMN?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling EVMN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Evommune, Inc.'s investment landscape.